Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1236265-10-3

4-((4-(3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-ylamino)methyl)-Nethyl-N-m-tolylbenzamide is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1236265-10-3 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1236265-10-3 Structure

  • Basic information

    1. Product Name: 4-((4-(3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-ylamino)methyl)-Nethyl-N-m-tolylbenzamide
    2. Synonyms: 4-((4-(3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-ylamino)methyl)-Nethyl-N-m-tolylbenzamide
    3. CAS NO:1236265-10-3
    4. Molecular Formula:
    5. Molecular Weight: 478.597
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1236265-10-3.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: 4-((4-(3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-ylamino)methyl)-Nethyl-N-m-tolylbenzamide(CAS DataBase Reference)
    10. NIST Chemistry Reference: 4-((4-(3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-ylamino)methyl)-Nethyl-N-m-tolylbenzamide(1236265-10-3)
    11. EPA Substance Registry System: 4-((4-(3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-ylamino)methyl)-Nethyl-N-m-tolylbenzamide(1236265-10-3)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1236265-10-3(Hazardous Substances Data)

1236265-10-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1236265-10-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,6,2,6 and 5 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1236265-10:
(9*1)+(8*2)+(7*3)+(6*6)+(5*2)+(4*6)+(3*5)+(2*1)+(1*0)=133
133 % 10 = 3
So 1236265-10-3 is a valid CAS Registry Number.

1236265-10-3Downstream Products

1236265-10-3Relevant articles and documents

Discovery of Potent and Selective Inhibitors for ADAMTS-4 through DNA-Encoded Library Technology (ELT)

Ding, Yun,O'Keefe, Heather,DeLorey, Jennifer L.,Israel, David I.,Messer, Jeffrey A.,Chiu, Cynthia H.,Skinner, Steven R.,Matico, Rosalie E.,Murray-Thompson, Monique F.,Li, Fan,Clark, Matthew A.,Cuozzo, John W.,Arico-Muendel, Christopher,Morgan, Barry A.

, p. 888 - 893 (2015/08/24)

The aggrecan degrading metalloprotease ADAMTS-4 has been identified as a novel therapeutic target for osteoarthritis. Here, we use DNA-encoded Library Technology (ELT) to identify novel ADAMTS-4 inhibitors from a DNA-encoded triazine library by affinity selection. Structure-activity relationship studies based on the selection information led to the identification of potent and highly selective inhibitors. For example, 4-(((4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-6-(((4-methylpiperazin-1-yl)methyl)amino)-1,3,5-triazin-2-yl)amino)methyl)-N-ethyl-N-(m-tolyl)benzamide has IC50 of 10 nM against ADAMTS-4, with >1000-fold selectivity over ADAMT-5, MMP-13, TACE, and ADAMTS-13. These inhibitors have no obvious zinc ligand functionality.

2,4-DIAMINO-1,3,5-TRIAZINE AND 4, 6-DIAMINO-PYRIMIDINE DERIVATIVES AND THEIR USE AS AGGRECANASE INHIBITORS

-

Page/Page column 93, (2010/08/08)

The invention is directed to compounds of formula (I): that modulate, e.g., inhibit, aggrecanase proteolytic activity, which is implicated in joint diseases including osteoarthritis, joint injury, reactive arthritis, acute pyrophosphate arthritis, psoriatic arthritis, and rheumatoid arthritis. The current invention also relates to processes for making the compounds of the invention and to pharmaceutical compositions containing these compounds. The present invention further provides methods of treating diseases associated with aggrecanase activity, e.g., osteoarthritis and other joint diseases, using the compounds of the invention.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1236265-10-3